Drug Trial Radar · NCT03853798
Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007
Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
90
Actual
Start
Mar 21, 2019
Primary completion
Jul 3, 2024
Study completion Jul 3, 2024
Sponsor
- Lead sponsor
- Agios Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 26, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter, extension study to evaluate the long-term safety, tolerability, and efficacy of treatment with mitapivat in participants who were previously enrolled in Study AG348-C-006 or Study AG348-C-007.
Conditions
- Pyruvate Kinase Deficiency
Interventions
MitapivatDrug
Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- All Cohorts: Number of Participants With at Least One Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Related TEAEs and TEAEs With Severity Greater Than or Equal to Grade 3Time frame: Up to 197 weeks
- All Cohorts: Number of Participants With TEAEs Leading to Dose Reduction, Treatment Interruption and Treatment DiscontinuationTime frame: Up to 197 weeks
- All Cohorts: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters Reported as Grade Greater Than or Equal to (≥)3 TEAEsTime frame: Up to 197 weeks
- All Cohorts: Number of Participants With Clinically Significant Abnormalities in Vital Signs Measurements and Physical Examinations Reported as TEAEsTime frame: Up to 197 weeks
- All Cohorts: Number of Participants With Clinically Significant Abnormalities in Bone Mineral Density (BMD)Time frame: Up to 192 weeks
- All Cohorts: Change From Baseline in Adjusted Spine T-scoreTime frame: Baseline, Week 192
- All Cohorts: Change From Baseline in Adjusted Spine Z-scoreTime frame: Baseline, Week 192
- All Cohorts: Change From Baseline in Femoral Total T-scoreTime frame: Baseline, Week 192
- All Cohorts: Change From Baseline in Femoral Total Z-scoreTime frame: Baseline, Week 192
- All Cohorts: Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Parameters Reported as TEAEsTime frame: Up to 197 weeks
Locations
42 sites in 16 countries. Site status is shown where the registry gives one.
Phoenix Children's Hospital
Phoenix, Arizona
UCSF Benioff Children's Hospital, Oakland
Oakland, California
Emory-Children's Center
Atlanta, Georgia
Indiana Hemophilia & Thrombosis Center Inc.
Indianapolis, Indiana
Massachusetts General Hospital
Boston, Massachusetts
Boston Children's Hospital
Boston, Massachusetts
Wayne State University School of Medicine
Detroit, Michigan
Duke University Medical Center
Durham, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Houston Methodist Research Institute
Houston, Texas
University of Utah
Salt Lake City, Utah
Seattle Cancer Care Alliance
Seattle, Washington
UNICAMP - Hemocentro
São Paulo, Brazil
McMaster University
Hamilton, Ontario, Canada
Herlev University Hospital
Herlev, Denmark
CHU Hopitaux de Bordeaux - Hôpital Saint-André
Bordeaux, France
CHU Hôpital Henri Mondor
Créteil, France
Hospital La Timone
Marseille, France
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, France
Charite - UB - CVK - Medizinische Klinik
Berlin, Germany
Universitätsklinik Würzburg
Würzburg, Germany
St James's Hospital
Dublin, Ireland
Ospedale Galliera
Genova, Italy
Osp Maggiore Policlinico Milano
Milan, Italy
AORN Cardarelli
Naples, Italy
Università della Campania "Luigi Vanvitelli"
Naples, Italy
Kyoto Katsura Hospital
Kyoto, Japan
Kansai Medical University, Dep. of Pediatrics, Hirakata Hospital
Osaka, Japan
Toho University Omori Medical Center
Tokyo, Japan
Mie University Hospital
Tsu, Mie-ken, Japan
Tohoku University Hospital
Sendai, Miyagi, Japan
Van Creveldkliniek
Utrecht, Netherlands
Yeungnam University Hospital
Daegu, South Korea
Hospital. U. Vall d'Hebron
Barcelona, Spain
Hospital Universitario La Paz
Madrid, Spain
Htal Clínico Universitario Virgen de la Arrixaca.
Murcia, Spain
Centre Hospitalier Universitaire Vaudois (CHUV)
Vaud (Lausanne), Switzerland
Faculty of Medicine Siriraj Hospital
Bangkok, Thailand
Hacettepe University Faculty of Medicine
Ankara, Turkey (Türkiye)
Addenbrooke's Hospital
Cambridge, United Kingdom
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.